{Reference Type}: Case Reports
{Title}: Role of rituximab as neoadjuvant therapy in a difficult case of relapsing pulmonary alveolar proteinosis.
{Author}: Marwah V;Choudhary R;Devarakonda BV;Malik V;
{Journal}: Med J Armed Forces India
{Volume}: 80
{Issue}: 3
{Year}: 2024 May-Jun
暂无{DOI}: 10.1016/j.mjafi.2022.10.005
{Abstract}: Pulmonary alveolar proteinosis (PAP) is a rare disease which involves the accumulation of insoluble lipoproteinaceous material in the alveoli leading to impaired gas exchange and even respiratory failure. Autoimmune PAP is the most common type and is characterized by the presence of anti-granulocyte-monocyte colony stimulating factor (anti GM-CSF) antibody. Whole lung lavage has been traditionally used as first-line management of PAP but there is a lack of clarity especially in the treatment of relapsing cases of PAP. Rituximab is an anti Cluster of Differentiate 20 (CD 20) monoclonal antibody that has been tried as salvage therapy for relapsing cases of PAP. We present a case of 35 years old female patient who was diagnosed as a case of relapsing PAP who was managed initially with neoadjuvant rituximab. This is a retrospective observational report showing novel use of neoadjuvant rituximab in a difficult case of relapsing PAP.